GSE111247 temozolomide LN-308 2 v 5 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE111247_temozolomide_LN-308_2_v_5_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE111247_temozolomide_LN-308_2_v_5_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE111247_temozolomide_LN-308_2_v_5_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE111247_temozolomide_LN-308_2_v_5_human_up.

Results found

Linked to

 

Label

Description

 

Gene

cytoskeleton regulator RNA

Gene

ARPIN-AP3S2 readthrough

Gene

family with sequence similarity 225 member A

Gene

uncharacterized LOC105371773

Gene

long intergenic non-protein coding RNA 2009

Gene

ETS repressor factor like

Gene

long intergenic non-protein coding RNA 1819

Gene

L-threonine dehydrogenase (pseudogene)

Gene

H4 clustered histone 4

Gene

PINK1 antisense RNA

  • Gene

    cytoskeleton regulator RNA


  • Gene

    ARPIN-AP3S2 readthrough


  • Gene

    family with sequence similarity 225 member A


  • Gene

    uncharacterized LOC105371773


  • Gene

    long intergenic non-protein coding RNA 2009


  • Gene

    ETS repressor factor like


  • Gene

    long intergenic non-protein coding RNA 1819


  • Gene

    L-threonine dehydrogenase (pseudogene)


  • Gene

    H4 clustered histone 4


  • Gene

    PINK1 antisense RNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.